Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
Value Health
; 25(12):S147, 2022.
Article
in English
| PubMed Central | ID: covidwho-2159394
Full text:
Available
Collection:
Databases of international organizations
Database:
PubMed Central
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Journal:
Value Health
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS